Firefly Neuroscience, Inc.(AIFF)Earnings, Financials & Key Ratios
AIFF•NASDAQ
Price updated Jun 19, 2026
AboutFirefly Neuroscience, Inc., a medical technology and artificial intelligence company, provides neuroscientific solutions that improve outcomes for patients with mental illnesses and neurological disorders. The company offers Brain Network Analytics, a software that focuses on diagnostic and treatment for people suffering from mental illnesses and cognitive disorders, including depression, dementia, anxiety disorders, concussions, and attention-deficit/hyperactivity disorder. It serves pharmaceutical companies and medical practitioners. Firefly Neuroscience, Inc. is based in Toronto, Canada.Show more
- Revenue$108K-78.3%
- EBITDA-$9M-252.7%
- Net Income-$10M-301.8%
- EPS (Diluted)-1.60-384.8%
- Gross Margin37.96%-62.0%
- EBITDA Margin-8437.96%-1526.2%
- Operating Margin-8500%-1275.2%
- Net Margin-9685.19%-1752.9%
AIFF Key Insights
Firefly Neuroscience, Inc. (AIFF) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Share count reduced 16.8% through buybacks
✗Weaknesses
- ✗Weak Piotroski F-Score: 3/9
- ✗Negative free cash flow
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when AIFF posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
AIFF Price & Volume
Firefly Neuroscience, Inc. (AIFF) stock price & volume — 10-year historical chart
Loading chart...
AIFF Growth Metrics
Firefly Neuroscience, Inc. (AIFF) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years50%
TTM-60.21%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-208.05%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-185.84%
Return on Capital
10 Years-1401.48%
5 Years-1401.48%
3 Years-2823.85%
Last Year-
AIFF Peer Comparison
Firefly Neuroscience, Inc. (AIFF) competitors in Vertical industry SaaS applications — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 MBRX | 118.79M | 2.88 | -0.10 | -319.85% | 0.02 | |||
 NRXP | 68.62M | 3.97 | -2.96 | -10.7% | ||||
 BTAI | 37.05M | 1.20 | -0.21 | -71.67% | -110.79% | |||
 NVAX | 1.5B | 9.13 | 3.59 | 64.69% | -14.73% | |||
 AXSM | 12.89B | 250.50 | -68.07 | 65.55% | -26.59% | -260.01% | 2.73 | |
 INVA | 1.66B | 22.49 | 6.82 | 18.52% | 118.91% | 47.59% | 0.23 | |
 SAVA | 63.77M | 1.32 | -2.54 | -95.77% | ||||
 PRAX | 8.15B | 282.31 | -20.94 | -100% | -43.02% | 0.00 |
Compare AIFF vs Peers
Firefly Neuroscience, Inc. (AIFF) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
AIFF Income Statement
Firefly Neuroscience, Inc. (AIFF) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|
Sales/Revenue | 13.9M | 32K | 0 | 498K | 108K | 783K |
Revenue Growth % | - | -99.77% | -100% | - | -78.31% | -60.21% |
Cost of Goods Sold | 11.69M | 0 | 0 | 0 | 67K | 267K |
COGS % of Revenue | 84.11% | - | - | - | 62.04% | - |
Gross Profit | 2.21M▲ 0% | 32K▼ 98.6% | 0▼ 100.0% | 498K▲ 0% | 41K▼ 91.8% | 516K▲ 0% |
Gross Margin % | 15.89% | 100% | - | 100% | 37.96% | 65.9% |
Gross Profit Growth % | - | -98.55% | -100% | - | -91.77% | - |
Operating Expenses | 1.8M | 4.69M | 3.33M | 3.58M | 9.22M | 10.31M |
OpEx % of Revenue | 12.93% | 14643.75% | - | 718.07% | 8537.96% | - |
Selling, General & Admin | 1.8M | 1.68M | 1.98M | 2.83M | 7.33M | 7.82M |
SG&A % of Revenue | 12.93% | 5253.13% | - | 569.28% | 6790.74% | - |
Research & Development | 0 | 2.93M | 1.27M | 741K | 1.95M | 1.46M |
R&D % of Revenue | - | 9143.75% | - | 148.8% | 1809.26% | - |
Other Operating Expenses | 0 | 79K | 77K | 0 | -67K | 1.03M |
Operating Income | 411.85K▲ 0% | -4.65M▼ 1230.0% | -3.33M▲ 28.5% | -3.08M▲ 7.5% | -9.18M▼ 198.2% | -9.79M▲ 0% |
Operating Margin % | 2.96% | -14543.75% | - | -618.07% | -8500% | -1250.45% |
Operating Income Growth % | - | -1230.03% | 28.47% | 7.54% | -198.25% | - |
EBITDA | 423.91K | -4.22M | -3.31M | -2.58M | -9.11M | -9.62M |
EBITDA Margin % | 3.05% | -13203.13% | - | -518.88% | -8437.96% | -1229.12% |
EBITDA Growth % | - | -1096.67% | 21.54% | 22.05% | -252.67% | -41.64% |
D&A (Non-Cash Add-back) | 12.06K | 429K | 14K | 0 | 67K | 167K |
EBIT | 413.38K | -4.25M | -3.21M | -2.58M | -10.39M | -19.68M |
Net Interest Income | 0 | -135K | -574K | -18K | -69K | -127K |
Interest Income | 0 | 0 | 0 | 0 | 0 | 59K |
Interest Expense | 0 | 135K | 574K | 18K | 69K | 186K |
Other Income/Expense | 1.53K | 273K | -460K | 476K | -1.28M | -11.39M |
Pretax Income | 413.38K▲ 0% | -4.38M▼ 1159.8% | -3.79M▲ 13.5% | -2.6M▲ 31.3% | -10.46M▼ 301.9% | -21.18M▲ 0% |
Pretax Margin % | 2.97% | -13690.63% | - | -522.49% | -9683.33% | -2705.11% |
Income Tax | 0 | 0 | 0 | 1K | 2K | 6K |
Effective Tax Rate % | 0% | 0% | 0% | -0.04% | -0.02% | -0.03% |
Net Income | 413.38K▲ 0% | -4.38M▼ 1159.8% | -3.79M▲ 13.5% | -2.6M▲ 31.3% | -10.46M▼ 301.8% | -21.19M▲ 0% |
Net Margin % | 2.97% | -13690.63% | - | -522.69% | -9685.19% | -2705.87% |
Net Income Growth % | - | -1159.8% | 13.51% | 31.3% | -301.84% | -208.05% |
Net Income (Continuing) | 413.38K | -4.38M | -3.79M | -2.6M | -10.46M | -21.19M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | 0.05▲ 0% | -0.56▼ 1166.7% | -0.48▲ 14.3% | -0.33▲ 31.2% | -1.60▼ 384.8% | -1.57▲ 0% |
EPS Growth % | - | -1166.67% | 14.29% | 31.25% | -384.85% | -185.84% |
EPS (Basic) | 0.05 | -0.56 | -0.48 | -0.33 | -1.60 | - |
Diluted Shares Outstanding | 7.87M | 7.87M | 7.87M | 7.87M | 6.55M | 13.5M |
Basic Shares Outstanding | 7.87M | 7.87M | 7.87M | 7.87M | 6.55M | 13.2M |
Dividend Payout Ratio | - | - | - | - | - | - |
AIFF Balance Sheet
Firefly Neuroscience, Inc. (AIFF) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|
Total Current Assets | 3.35M | 703K | 83K | 2.25M | 2.63M | 5.43M |
Cash & Short-Term Investments | 1.86M | 653K | 58K | 2.14M | 1.81M | 4.33M |
Cash Only | 1.86M | 653K | 58K | 2.14M | 1.81M | 4.33M |
Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts Receivable | 1.44M | 41K | 19K | 84K | 121K | 0 |
Days Sales Outstanding | 37.86 | 467.66 | - | 61.57 | 408.94 | 48.71 |
Inventory | 0 | 0 | 0 | 0 | 0 | 80K |
Days Inventory Outstanding | - | - | - | - | - | 72.79 |
Other Current Assets | 27.63K | 0 | 0 | 0 | 280K | 184K |
Total Non-Current Assets | 419.61K | 250K | 52K | 386K | 1.97M | 6.98M |
Property, Plant & Equipment | 113.57K | 188K | 0 | 0 | 136K | 235K |
Fixed Asset Turnover | 122.42x | 0.17x | - | - | 0.79x | 4.89x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 5.17M |
Intangible Assets | 0 | 1K | 0 | 386K | 180K | 898K |
Long-Term Investments | 210.69K | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 95.35K | 61K | 52K | 0 | 1.66M | 669K |
Total Assets | 3.77M▲ 0% | 953K▼ 74.7% | 135K▼ 85.8% | 2.64M▲ 1856.3% | 4.6M▲ 74.2% | 12.41M▲ 0% |
Asset Turnover | 3.68x | 0.03x | - | 0.19x | 0.02x | 0.07x |
Asset Growth % | - | -74.75% | -85.83% | 1856.3% | 74.21% | 787.53% |
Total Current Liabilities | 1.8M | 3.97M | 2.25M | 2.53M | 4.98M | 2.72M |
Accounts Payable | 103.65K | 500K | 420K | 630K | 1.82M | 1.34M |
Days Payables Outstanding | 3.24 | - | - | - | 9.89K | 2.14K |
Short-Term Debt | 138.6K | 1.79M | 0 | 0 | 694K | 0 |
Deferred Revenue (Current) | 946.88K | 459K | 909K | 0 | 13K | 296K |
Other Current Liabilities | 57.4K | 0 | 0 | 0 | 827K | 716K |
Current Ratio | 1.86x | 0.18x | 0.04x | 0.89x | 0.53x | 2.00x |
Quick Ratio | 1.86x | 0.18x | 0.04x | 0.89x | 0.53x | 1.97x |
Cash Conversion Cycle | - | - | - | - | - | -2.02K |
Total Non-Current Liabilities | 356.99K | 0 | 0 | 0 | 0 | 31K |
Long-Term Debt | 356.99K | 0 | 0 | 0 | 0 | 0 |
Capital Lease Obligations | 0 | 0 | 0 | 0 | 0 | 0 |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 31K |
Total Liabilities | 2.16M | 3.97M | 2.25M | 2.53M | 4.98M | 2.75M |
Total Debt | 495.6K | 1.79M | 0 | 0 | 694K | 0 |
Net Debt | -1.36M | 1.14M | -58K | -2.14M | -1.12M | -4.33M |
Debt / Equity | 0.31x | - | - | - | - | 0.00x |
Debt / EBITDA | 1.17x | - | - | - | - | -0.00x |
Net Debt / EBITDA | -3.21x | - | - | - | - | 0.45x |
Interest Coverage | - | -34.47x | -5.80x | -171.00x | -133.04x | -105.82x |
Total Equity | 1.61M▲ 0% | -3.01M▼ 286.8% | -2.11M▲ 30.0% | 109K▲ 105.2% | -375K▼ 444.0% | 9.66M▲ 0% |
Equity Growth % | - | -286.81% | 29.96% | 105.16% | -444.04% | 784.74% |
Book Value per Share | 0.20 | -0.38 | -0.27 | 0.01 | -0.06 | 0.72 |
Total Shareholders' Equity | 1.61M | -3.01M | -2.11M | 109K | -375K | 9.66M |
Common Stock | 129.04K | 0 | 19K | 0 | 0 | 1K |
Retained Earnings | -12.31M | -67.33M | -73.91M | -76.62M | -87.08M | -108.9M |
Treasury Stock | -930.21K | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 |
AIFF Cash Flow Statement
Firefly Neuroscience, Inc. (AIFF) cash flow — operating, investing & free cash flow history
| Metric | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|
Cash from Operations | 423.26K | -3.82M | -2.89M | -2.17M | -6.16M | -7.61M |
Operating CF Margin % | 3.04% | -11937.5% | - | -436.14% | -5699.07% | - |
Operating CF Growth % | - | -1002.51% | 24.29% | 24.9% | -183.38% | -305.74% |
Net Income | 413.38K | -4.38M | -3.79M | -2.6M | -10.46M | -21.19M |
Depreciation & Amortization | 12.06K | 429K | 14K | 0 | 67K | 179K |
Stock-Based Compensation | 0 | 608K | 60K | 295K | 2.72M | 403K |
Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 27.63K | -283K | 432K | 0 | 1.07M | 12.92M |
Working Capital Changes | -29.8K | -193K | 391K | 136K | 445K | 75K |
Change in Receivables | -984.21K | 26K | 27K | -65K | -37K | 71K |
Change in Inventory | 0 | 0 | 0 | 0 | 0 | 28K |
Change in Payables | -112.58K | 206K | -80K | 35K | 883K | -166K |
Cash from Investing | -64.55K | 1.6M | 262K | -386K | -477K | -2.54M |
Capital Expenditures | -64.55K | 0 | 0 | -386K | -148K | -185K |
CapEx % of Revenue | 0.46% | - | - | 77.51% | 137.04% | 23.63% |
Acquisitions | 0 | 0 | 0 | 0 | 0 | -2.36M |
Investments | - | - | - | - | - | - |
Other Investing | 0 | 597K | 262K | 0 | -329K | 4K |
Cash from Financing | 460K | 2.04M | 2.04M | 4.64M | 6.3M | 13.24M |
Debt Issued (Net) | 450K | 2.04M | 1.75M | 0 | 1.96M | 1.96M |
Equity Issued (Net) | 10K | 0 | 290K | 1000K | 1000K | 1.9M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | -19K |
Other Financing | 0 | 0 | 0 | 0 | 36K | 8.83M |
Net Change in Cash | 818.72K▲ 0% | -181K▼ 122.1% | -595K▼ 228.7% | 2.08M▲ 450.4% | -333K▼ 116.0% | 3.1M▲ 0% |
Free Cash Flow | 358.72K▲ 0% | -3.82M▼ 1164.9% | -2.89M▲ 24.3% | -2.56M▲ 11.5% | -6.57M▼ 156.8% | -7.79M▲ 0% |
FCF Margin % | 2.58% | -11937.5% | - | -513.65% | -6083.33% | -995.15% |
FCF Growth % | - | -1164.9% | 24.29% | 11.55% | -156.84% | -31.55% |
FCF per Share | 0.05 | -0.49 | -0.37 | -0.33 | -1.00 | -0.58 |
FCF Conversion (FCF/Net Income) | 1.02x | 0.87x | 0.76x | 0.83x | 0.59x | 0.37x |
Interest Paid | 0 | 0 | 0 | 0 | 11K | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 |
AIFF Key Ratios
Firefly Neuroscience, Inc. (AIFF) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|
Return on Equity (ROE) | - | - | -2388.07% | - | -219.4% |
Return on Invested Capital (ROIC) | - | - | - | - | -518.68% |
Gross Margin | 100% | - | 100% | 37.96% | 65.9% |
Net Margin | -13690.63% | - | -522.69% | -9685.19% | -2705.87% |
Debt / Equity | - | - | - | - | 0.00x |
Interest Coverage | -34.47x | -5.80x | -171.00x | -133.04x | -105.82x |
FCF Conversion | 0.87x | 0.76x | 0.83x | 0.59x | 0.37x |
Revenue Growth | -99.77% | -100% | - | -78.31% | -60.21% |
Related:AIFF Dividend History·AIFF Revenue History·AIFF Price History·AIFF P/E History·AIFF Financial Ratios·AIFF Institutional Holders
AIFF Frequently Asked Questions
Firefly Neuroscience, Inc. (AIFF) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Firefly Neuroscience, Inc. (AIFF) reported $0.8M in revenue for fiscal year 2024. This represents a 94% decrease from $13.9M in 2020.
Firefly Neuroscience, Inc. (AIFF) saw revenue decline by 78.3% over the past year.
Firefly Neuroscience, Inc. (AIFF) reported a net loss of $21.2M for fiscal year 2024.
Dividend & Returns
Firefly Neuroscience, Inc. (AIFF) had negative free cash flow of $7.8M in fiscal year 2024, likely due to heavy capital investments.